

ISSN 2181-5887



O'ZBEKISTON TERAPIYA AXBOROTNOMASI



ТЕРАПЕВТИЧЕСКИЙ ВЕСТНИК УЗБЕКИСТАНА

№ 2, 2023

O'zbekiston terapevtlar Assotsiatsiyasi
Ассоциация терапевтов Узбекистана

ISSN 2181–5887

O'ZBEKISTON TERAPIYA AXBOROTNOMASI

Ilmiy-amaliy jurnal

2023. № 2

ТЕРАПЕВТИЧЕСКИЙ ВЕСТНИК УЗБЕКИСТАНА

Научно-практический журнал

РАННЕЕ ВЫЯВЛЕНИЕ ДИСФУНКЦИИ ЛЕВОГО ЖЕЛУДОЧКА У ПАЦИЕНТОВ С ПОДОЗРЕНИЕМ НА ИШЕМИЧЕСКУЮ БОЛЕЗНЬ СЕРДЦА: СРАВНЕНИЕ КЛАССИЧЕСКОЙ ЭХОКАРДИОГРАФИИ И МЕТОДА СПЕКЛ ТРЕКИНГА Убайдуллаева Ш.М., Аляви Б.А., Кенжаев С.Р.	41
ҚАНДЛИ ДИАБЕТ ФОНИДА КЕЧАЁТГАН ЮРАК ИШЕМИК КАСАЛЛИГИ БИЛАН ОҒРИГАН БЕМОЛЛАРДА COVID-19 ДАН КЕЙИНГИ ЭНДОТЕЛИЙ ФАОЛИЯТИНИНГ КЎРСАТКИЧЛАРИ Убайдуллаев Ш.А., Аляви А.Л.	42
СРАВНЕНИЕ ТЕРАПИИ ФЕБУКСОСТАТОМ И АЛЛОПУРИНОЛОМ БЕССИМПТОМНОЙ ГИПЕРУРИКЕМИИ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ Умматалиева Н.М., Ахмедов Х.С.	42
КОМОРБИДНЫЕ СОСТОЯНИЯ У БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ ПО ДАННЫМ РЕТРОСПЕКТИВНОГО АНАЛИЗА Умматалиева Н.М., Гадаев А.Г., Пирматова Н.В.	43
РЕЖАЛИ РАВИШДА АМАЛИЁТГА ТАЙЁРЛАНГАН БЕМОЛЛАРДА КАРДИОВАСКУЛЯР АСОРАТЛАРНИ ПРОФИЛАКТИКАСИ Умаров А.Э., Отамирзаев Н.Р., Фозилов А.В.	44
РЕАБИЛИТАЦИЯ ПАЦИЕНТОВ ПОСЛЕ ИНФАРКТА МИОКАРДА Үсен Н.Ү, Сулейменов А.К. Сейсембеков Т.З.	44
ИЗУЧЕНИЕ ВЛИЯНИЯ СТАТИНОТЕРАПИИ НА ЛИПИДЫ И ЭЛЕКТРОКАРДИОГРАФИЧЕСКИЕ ПАРАМЕТРЫ БОЛЬНЫХ ПРИ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ Фазылов А.В., Аляви А.Л., Ибрагимов А.Ю., Турсунов Х.Х., Пулатов Н.Н.	45
СУТОЧНОЕ КОЛЕБАНИЕ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ У БОЛЬНЫХ АТЕРОСКЛЕРОЗОМ СОННЫХ АРТЕРИЙ ПРИ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ Фазылов А.В., Аляви Б.А., Салохитдинов З.С., Ибабекова Ш.Р., Абдулахонова Ш.Ж.	46
РЕМОДЕЛИРОВАНИЕ ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ: СВЯЗЬ С КЛИНИКО-ИММУНОЛОГИЧЕСКИМИ ОСОБЕННОСТЯМИ ЗАБОЛЕВАНИЯ И НАЛИЧИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ Халилова Д.А., Каримова Г.Н.	47
ФАКТОРЫ, СПОСОБСТВУЮЩИЕ ПРОГРЕССИРОВАНИЮ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У БОЛЬНЫХ С ПОЧЕЧНОЗАМЕСТИТЕЛЬНОЙ ТЕРАПИЕЙ Хасанов К.Х., Касымов Б.З., Фазылов А.В.	47
ВЛИЯНИЕ ВОЗРАСТА НА АГРЕГАЦИОННУЮ АКТИВНОСТЬ ТРОМБОЦИТОВ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА Ходжанова Ш.И., Аляви А.Л.	48
ҚАНДЛИ ДИАБЕТ 2-ТИПИ БИЛАН КАСАЛЛАНГАН БЕМОЛЛАРДА ИНФАРКТДАН КЕЙИНГИ РЕМОДЕЛЛАНИШ ЖАРАЁНИНИ БАҲОЛАШ Хусанов Р.А. Рахимов Х.Х., Нуритдинов Н.А., Камилова У.К.	49
АМЛОДИПИН МАЛЕАТ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ В СОЧЕТАНИИ С ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ Чапау А.Х., Оджарова Б.Г., Овезова М.А., Шихмурадова Г.А.	49
ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ И ЕЁ КОРРЕКЦИЯ С ПРИМЕНЕНИЕМ КОМБИНАЦИИ ПРЕПАРАТОВ ОЛМЕСАРТАН/ЛЕРКАНИДИПИН Шоалимова З.М., Нуритдинова Н.Б.	50
СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИ БИЛАН ХАСТАЛАНГАН БЕМОЛЛАРДА ДАВОЛОВЧИ ЖИСМОНИЙ ТАРБИЯ МАШҒУЛОТЛАРИНИ ҚЎЛЛАШ Юнусова Н.Ш., Камилова У.К., Тагаева Д.Р.	51
МИОКАРД ИНФАРКТИДА ЭНДОТЕЛИАЛ NO – СИНТАЗА ГЕНИ ХУСУСИЯТЛАРИНИ ЎРГАНИШ Юсупов Д.М., Бобоев К.Т., Камилова У.К.	51
СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ КОРРЕКЦИИ НЕКОНТРОЛИРУЕМОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ Юсупова З.К., Агабабян И.Р.	52
CARDIORENAL RELATIONSHIPS IN PATIENTS WITH CHRONIC HEART FAILURE Boqiyeva D.R., Jabbarov O.O., Khodjanova Sh.I., Maksudova M.X., Kadirova Sh.A.	53
THE ROLE OF REGULAR PHYSICAL ACTIVITY IN THE PREVENTION OF VENTRICULAR EXTRASYSTOLES Ismoilov U.I., Nurillaeva N.M., Shukurdjanova S.M.	53
CHANGES IN THE NATURE OF THE COURSE OF ARTERIAL HYPERTENSION AND ITS THERAPY IN PATIENTS WHO WERE IN THE ZONE OF COMBAT ACTIONS IN THE TERRITORY OF THE KHARKOV REGION OF UKRAINE Koval S.M., Rieznik L.A., Starchenko T.G., Mysnychenko O.V.	54
ANTIHYPERTENSIVE THERAPY IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE Mirzaeva G.P., Umarova Z.F., Saydaliev R.S., Nadirova Yu.I.	55
ASSESSMENT OF THE FUNCTIONAL STATE OF THE LIVER IN PATIENTS WITH CHD AND OPTIMIZATION OF WAYS OF CORRECTION Parpibayeva D.A., Buvamukhamedova N.T., Ergashov N.Sh.	55
EFFECT OF KIDNEY TRANSPLANTATION ON LEFT VENTRICULAR REMODELING AND RISK FACTORS FOR POSTTRANSPLANT LEFT VENTRICULAR HYPERTROPHY Salyamova F.E., Sabirov M.A.	56
QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME Sobirov A.A., Xushnazarov Q.E., Akbarov T.Y., Sultonova N.A.	56

ANTIHYPERTENSIVE THERAPY IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

MIRZAEVA G.P., UMAROVA Z.F., SAYDALIEV R.S., NADIROVA YU.I.

Tashkent Medical Academy, Tashkent, Uzbekistan

Methods. We analyzed 75 case histories of elderly patients treated in the nephrology department of the 3-clinic of the Tashkent medical academy. The average duration of hospitalization was $12,79 \pm 0,26$ days. The mean age of patients was $66,24 \pm 0,56$ years (60% – women). AH of the 1st degree was revealed in 4% of patients, AH of the 2nd degree – in 36%, AH of the 3rd degree – in 60%. Stage II CKD had 2.7% of patients, stage III CKD – 61.3%, stage IV CKD – 28%, stage V CKD – 8%. Proteinuria less than 300 mg/day was detected in 24% of patients, proteinuria 300–3000 mg/day in 32%, and proteinuria over 3000 mg/day in 5.3%. Pharmacotherapy was analyzed by prescription sheets.

Results. Combined antihypertensive therapy was administered in 97.3% of patients. The average number of simultaneously prescribed antihypertensive drugs per patient was 3.12 ± 0.14 . Beta-adrenoblockers (BABs) were given to 70.7% of the patients (of which bisoprolol in 58.5% of cases, metoprolol in 32.1%, nebivolol in 5.7%, atenolol in 3.8%, and carvedilol in 3.8%). Calcium antagonists (CA) were administered in 69.3% of patients (including amlodipine in 76.9%, nifedipine in extended forms in 14.7%). Diuretics (D) were received orally by 65.3% of patients (indapamide – 71.4%, furosemide – 22.4%, thorasemide –

18.4%, spironolactone – 6.1%). In addition, 14.7% of patients received intravenous furosemide. ARBs were prescribed in 45.3% of patients (fosinopril – 61.8%, enalapril – 41.2%). Centrally acting drugs were received by 25.3% of patients (rilmenidine – 68.4%, moxonidine – 38.5%). ARBs were received by 26.7% of patients (losartan – 90%, telmisartan – 5%, eprosartan – 5%). 6.7% of patients received the alpha-adrenoblocker doxazosin. In 18 cases, when ACEIs were not used, ARBs were prescribed. Thus, the total number of patients who received nephroprotective drugs (ACEIs and BRA) was 69.3%. The incidence of hyperkalemia was 39.1% and the incidence of stage V CKD was 34.8% in the group of patients who received neither (ACEIs) nor ARBs. During the performed therapy, blood pressure (BP) significantly decreased from $157.79 \pm 3.02/92.27 \pm 1.18$ to $128.47 \pm 1.07/82.33 \pm 0.83$ mm Hg. Target BP (target BP (<140/80 mm Hg) at the time of discharge was achieved in 53.3% of patients.

Conclusion. The majority of elderly patients with CKD and AH received nephroprotective drugs (ACEIs and ARBs), which is in line with the current recommendations. In 30.7% of patients they were not prescribed, apparently due to hyperkalemia and the presence of marked azotemia.

ASSESSMENT OF THE FUNCTIONAL STATE OF THE LIVER IN PATIENTS WITH CHD AND OPTIMIZATION OF WAYS OF CORRECTION

PARPIBAYEVA D.A., BUVAMUKHAMEDOVA N.T., ERGASHOV N.SH.

Tashkent Medical Academy, Tashkent, Uzbekistan

Purpose of the study. In this connection the aim of our study was to investigate the parameters of liver function in patients with stable angina II–III on the background of combined therapy with atorvastatin and milk thistle extract.

Materials and methods. The study included 80 patients with stable angina II–III. All patients were divided into 2 groups. 42 patients with stable angina II–III functional class (FC) who received standard therapy together with milk thistle extract were included into the main group (I group). The control group included 38 patients with CHD (Chronic heart disease) who received only basic therapy without milk thistle extract. The study was conducted in the departments of cardiology and cardiac rehabilitation of 3 clinics of Tashkent Medical Academy. All patients were taking drugs for stable angina according to the standards: antianginal drugs, B-blockers, ACE inhibitors, statins, anticoagulants, antiaggregants. All patients were

prescribed atorvastatin 20 mg in the evening after dinner, and patients in the main group took milk thistle extract (30 mg silymarin) for 3 months (1 tablet 2 times a day with meals).

All patients before and after treatment, along with general clinical tests had OAC, AML, biochemical blood tests, including ALT, AST level, total bilirubin, Serological screening for viral hepatitis (HBsAg, anti-HCV), blood lipid spectrum (triglycerides, total cholesterol, HDL-C, LDL-C), coagulogram, ECG, Holter monitoring were studied. Intracardiac hemodynamic parameters were determined by EchoCG.

Results of the study. against the background of therapy with atorvastatin together with milk thistle extract after 3 months the liver transaminases values were observed in comparison with the initial indices, there was a tendency to decrease the mean level of cytotoxic markers: after 3 months the mean level of